"Dabigatran" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A THROMBIN inhibitor which acts by binding and blocking thrombogenic activity and the prevention of thrombus formation. It is used to reduce the risk of stroke and systemic EMBOLISM in patients with nonvalvular atrial fibrillation.
| Descriptor ID |
D000069604
|
| MeSH Number(s) |
D03.383.725.192 D03.633.100.103.280
|
| Concept/Terms |
Dabigatran- Dabigatran
- N-((2-(((4-(aminoiminomethyl)phenyl)amino)methyl)-1-methyl-1H-benzimidazol-5-yl)carbonyl)-N-2-pyridinyl-beta-alanine
|
Below are MeSH descriptors whose meaning is more general than "Dabigatran".
Below are MeSH descriptors whose meaning is more specific than "Dabigatran".
This graph shows the total number of publications written about "Dabigatran" by people in this website by year, and whether "Dabigatran" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 0 | 1 | 1 |
| 2011 | 0 | 3 | 3 |
| 2013 | 0 | 2 | 2 |
| 2014 | 0 | 2 | 2 |
| 2016 | 2 | 0 | 2 |
| 2018 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dabigatran" by people in Profiles.
-
Anticoagulant Therapy for Mechanical Heart Valves - Unmet Need Persists. NEJM Evid. 2023 Jul; 2(7):EVIDe2300106.
-
Whole Blood Point-of-Care Testing for Incomplete Reversal With Idarucizumab in Supratherapeutic Dabigatran. Anesth Analg. 2020 02; 130(2):535-541.
-
Upper Gastrointestinal Bleeding in a Male Patient Taking Megestrol Acetate and Rivaroxaban: A Case Report. Sr Care Pharm. 2019 Sep 01; 34(8):501-509.
-
The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations. Thromb Haemost. 2019 Jan; 119(1):14-38.
-
Extension of Disease Risk Score-Based Confounding Adjustments for Multiple Outcomes of Interest: An Empirical Evaluation. Am J Epidemiol. 2018 11 01; 187(11):2439-2448.
-
Simulation for Predicting Effectiveness and Safety of New Cardiovascular Drugs in Routine Care Populations. Clin Pharmacol Ther. 2018 11; 104(5):1008-1015.
-
Generalized boosted modeling to identify subgroups where effect of dabigatran versus warfarin may differ: An observational cohort study of patients with atrial fibrillation. Pharmacoepidemiol Drug Saf. 2018 04; 27(4):383-390.
-
RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate. Thromb Haemost. 2017 01 26; 117(2):415-421.
-
Prediction of rates of thromboembolic and major bleeding outcomes with dabigatran or warfarin among patients with atrial fibrillation: new initiator cohort study. BMJ. 2016 May 24; 353:i2607.
-
Idarucizumab for Dabigatran Reversal in Emergency Type-A Aortic Dissection. J Cardiothorac Vasc Anesth. 2017 12; 31(6):e80-e81.